Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2003 1
2004 1
2005 1
2006 1
2007 6
2008 5
2009 4
2010 1
2011 2
2012 2
2013 3
2014 3
2015 6
2016 1
2017 1
2018 6
2019 2
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

45 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS. Gage BF, et al. JAMA. 2017 Sep 26;318(12):1115-1124. doi: 10.1001/jama.2017.11469. JAMA. 2017. PMID: 28973620 Free PMC article. Clinical Trial.
Whether genotype-guided warfarin dosing can prevent these adverse events is unknown. ...CONCLUSIONS AND RELEVANCE: Among patients undergoing elective hip or knee arthroplasty and treated with perioperative warfarin, genotype-guided warfarin dosi …
Whether genotype-guided warfarin dosing can prevent these adverse events is unknown. ...CONCLUSIONS AND RELEVANCE: Among patie …
Genotype and risk of major bleeding during warfarin treatment.
Kawai VK, Cunningham A, Vear SI, Van Driest SL, Oginni A, Xu H, Jiang M, Li C, Denny JC, Shaffer C, Bowton E, Gage BF, Ray WA, Roden DM, Stein CM. Kawai VK, et al. Pharmacogenomics. 2014 Dec;15(16):1973-83. doi: 10.2217/pgs.14.153. Pharmacogenomics. 2014. PMID: 25521356 Free PMC article.
AIM: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy. ...CONCLUSION: The CYP2C9*3 allele may double the risk of major
AIM: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of …
Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.
Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Anderson JL, Li J, Rodriguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS. Gage BF, et al. JAMA. 2019 Sep 3;322(9):834-842. doi: 10.1001/jama.2019.12085. JAMA. 2019. PMID: 31479138 Free PMC article. Clinical Trial.
INTERVENTIONS: In a 2 2 factorial design, participants were randomized to a target INR of 1.8 (n = 823) or 2.5 (n = 827) and to either genotype-guided or clinically guided warfarin dosing. For the first 11 days of therapy, open-label warfarin dosing wa …
INTERVENTIONS: In a 2 2 factorial design, participants were randomized to a target INR of 1.8 (n = 823) or 2.5 (n = 827) and to either ge
Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
Ng SS, Lai NM, Nathisuwan S, Jahan NK, Dilokthornsakul P, Kongpakwattana K, Hollingworth W, Chaiyakunapruk N. Ng SS, et al. Sci Rep. 2020 Jan 20;10(1):662. doi: 10.1038/s41598-019-57370-2. Sci Rep. 2020. PMID: 31959803 Free PMC article.
Warfarin care bundles (e.g. genotype-guided warfarin dosing, patient's self-testing [PST] or patient's self-management [PSM] and left atrial appendage closure) are based on the concept of combining several interventions to improve anticoagulatio
Warfarin care bundles (e.g. genotype-guided warfarin dosing, patient's self-testing [PST] or patient's se
The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
Tomek A, Maťoška V, Kolářová T, Neumann J, Srámek M, Sarbochová I, Táborský L, Bojar M, Goetz P, Serebruany VL. Tomek A, et al. Cardiology. 2013;125(3):182-91. doi: 10.1159/000350407. Epub 2013 Jun 12. Cardiology. 2013. PMID: 23774101
BACKGROUND: Warfarin is commonly used for the treatment and prevention of arterial and venous thromboembolism but its use is hindered by the risk of bleeding. The main reason for this risk is a narrow therapeutic index and a wide response variab …
BACKGROUND: Warfarin is commonly used for the treatment and prevention of arterial and venous thromboembolism but its use is h …
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.
Roth JA, Bradley K, Thummel KE, Veenstra DL, Boudreau D. Roth JA, et al. Pharmacoepidemiol Drug Saf. 2015 Jun;24(6):619-27. doi: 10.1002/pds.3769. Epub 2015 Apr 8. Pharmacoepidemiol Drug Saf. 2015. PMID: 25858232 Free PMC article.
We conducted a case-control study to assess the association between screening positive for moderate/severe alcohol misuse and the risk of major bleeding in a community sample of patients using warfarin. ...Stratified analyses demonstrated increased alc …
We conducted a case-control study to assess the association between screening positive for moderate/severe alcohol misuse and the risk
Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials.
Yang T, Zhou Y, Chen C, Lu M, Ma L, Cui Y. Yang T, et al. J Clin Pharm Ther. 2019 Apr;44(2):197-208. doi: 10.1111/jcpt.12782. Epub 2018 Dec 28. J Clin Pharm Ther. 2019. PMID: 30593674 Review.
WHAT IS KNOWN AND OBJECTIVE: Genotype-guided warfarin dosing algorithm is designed to predict the initial and stable dose of warfarin. ...Risk of bias of eligible RCTs was assessed with the Cochrane Collaboration's tool. ...
WHAT IS KNOWN AND OBJECTIVE: Genotype-guided warfarin dosing algorithm is designed to predict the initial and stable dose of …
Genotype-guided warfarin therapy: Still of only questionable value two decades on.
Shah RR. Shah RR. J Clin Pharm Ther. 2020 Jun;45(3):547-560. doi: 10.1111/jcpt.13127. Epub 2020 Mar 13. J Clin Pharm Ther. 2020. PMID: 32168383
METHODS: Major widely-cited warfarin pharmacogenetic studies as well as recent meta-analyses were identified and a critical analysis of these was undertaken to identify factors that may account for poor clinical implementation of pre-treatment genotyping
METHODS: Major widely-cited warfarin pharmacogenetic studies as well as recent meta-analyses were identified and a critical an …
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP, Day CP, Kesteven PJ, Daly AK. Aithal GP, et al. Lancet. 1999 Feb 27;353(9154):717-9. doi: 10.1016/S0140-6736(98)04474-2. Lancet. 1999. PMID: 10073515
Patients in the low-dose group were more likely to have difficulties at the time of induction of warfarin therapy (5.97 [2.26-15.82]) and have increased risk of major bleeding complications (rate ratio 3.68 [1.43-9.50]) when compared with random …
Patients in the low-dose group were more likely to have difficulties at the time of induction of warfarin therapy (5.97 [2.26- …
Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.
Yang J, Chen Y, Li X, Wei X, Chen X, Zhang L, Zhang Y, Xu Q, Wang H, Li Y, Lu C, Chen W, Zeng C, Yin T. Yang J, et al. Int J Cardiol. 2013 Oct 9;168(4):4234-43. doi: 10.1016/j.ijcard.2013.07.151. Epub 2013 Aug 7. Int J Cardiol. 2013. PMID: 23932037 Review.
BACKGROUND: The main challenge for warfarin anticoagulation is the risk for hemorrhagic complications. ...CYP2C9*3 is the main genetic risk factor for warfarin hemorrhagic complications....
BACKGROUND: The main challenge for warfarin anticoagulation is the risk for hemorrhagic complications. ...CYP2C9*3 is the main …
45 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback